Cellid, Co., Ltd.

KOSDAQ 299660.KQ

Cellid, Co., Ltd. Gross Profit for the year ending December 31, 2023: USD -2.05 M

Cellid, Co., Ltd. Gross Profit is USD -2.05 M for the year ending December 31, 2023, a -8.86% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Cellid, Co., Ltd. Gross Profit for the year ending December 31, 2022 was USD -1.88 M, a -62.81% change year over year.
Cellid, Co., Ltd. Gross Profit for the year ending December 31, 2021 was USD -1.15 M, a -155.54% change year over year.
Cellid, Co., Ltd. Gross Profit for the year ending December 31, 2020 was USD -451.65 K, a -378.46% change year over year.
Cellid, Co., Ltd. Gross Profit for the year ending December 31, 2019 was USD -94.40 K, a -37.95% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

KOSDAQ: 299660.KQ

Cellid, Co., Ltd.

CEO	Yuil Kang Chang
IPO Date	Feb. 19, 2019
Location	South Korea
Headquarters	Building 142, Korea Seoul National University
Employees	64
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.

Key trends

Past 5 years